Market Overview:
The global oral hypoglycemic agents and insulin analogues market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about oral hypoglycemic agents and insulin analogues, and technological advancements in the field of diabetes treatment. Based on type, the global oral hypoglycemic agents and insulin analogues market is segmented into insulin secretagogues, alpha-glucosidase inhibitors, and insulin sensitizers. Insulin secretagogues are further sub-segmented into sulfonylureas, meglitinides, glinides, dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), glucagon-like peptide 1 receptor agonists (GLP1RA), and other types of insulin secretagogues. Alpha-glucosidase inhibitors are further sub-segmented into acarbose and miglitol. Insulin sensitizers are further sub segmented into thiazolidinediones (TZDs)and biguanides/metformin hydrochloride . Based on application ,the global oral hypoglycemic agents amdinsulin analoguesmarket is segmentedinto hospitals ,drug stores ,and others .
Product Definition:
Oral hypoglycemic agents are medications that lower blood sugar levels in people with diabetes mellitus. They work by stimulating the release of insulin from the pancreas, or by preventing the absorption of glucose from the intestines. Insulin analogues are synthetic forms of insulin that have been designed to more closely mimic the natural hormone. They are used to treat type 1 and type 2 diabetes, as well as gestational diabetes.
Insulin Secretagogues:
Insulin secretagogues are the oral hypoglycemic agents that stimulate insulin secretion from the pancreas. They enable lower blood sugar levels by promoting hepatic glucose production and inhibiting glucagon-induced inhibition of insulin release from pancreatic cells. The most commonly used drug is Byetta, which was approved in 2002 in Europe and 2003 in U.S.
Alpha-glucosidase Inhibitors:
Alpha-glucosidase inhibitors are glycosidic drugs that inhibit the enzyme alpha-glucosidase, which is involved in the hydrolysis of glucagon to form active insulin and free glucose. The drug class includes avanafil, vardenafil, and tazobactam.
Application Insights:
Based on application, the global market is segmented into hospitals, retail pharmacies and drug stores, others. Hospitals held the largest share in 2017 owing to factors such as a high prevalence of diabetes and increasing awareness among patients about availability of early treatment for type 2 diabetes.
Drug stores are anticipated to witness lucrative growth over the forecast period due to rising demand for oral hypoglycemic agents outside hospital settings. Increasing consumer awareness regarding self-management of chronic diseases such as diabetes is also expected to boost product demand in this segment over the forecast period.
Owing to stringent regulations regarding use of insulin analogues in developed countries such as U.S., Canada, Germany etc.
Regional Analysis:
Asia Pacific dominated the global market in 2017 and is expected to continue its dominance over the forecast period. The presence of a large target population, availability of advanced healthcare facilities, rising prevalence of diabetes complications, and increasing demand for cost-effective treatment options are some major factors driving regional growth. In addition, growing awareness about oral hypoglycemic agents and insulin analogues among patients is anticipated to further fuel revenue generation in this region.
North America accounted for a significant share owing to high R&D investments by leading pharmaceutical companies coupled with extensive clinical trials being conducted on new drug molecules pertaining to diabetes management strategies. Moreover, favorable government initiatives such as the launch of new insurance programs that cover oral anti-diabetic drugs are also expected to drive regional growth during the forecast period.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing at an alarming rate. This is primarily due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increased demand for oral hypoglycemic agents and insulin analogues to manage blood sugar levels in diabetic patients.
- Technological advancements in oral hypoglycemic agents and insulin analogues: Pharmaceutical companies are constantly investing in research and development to develop new and better oral hypoglycemic agents and insulin analogues that are more effective, safer, and easier to use. This has led to several technological advancements in this market, which is helping it grow at a rapid pace.
- Growing awareness about diabetes mellitus: There has been a growing awareness about diabetes mellitus among people around the world in recent years. This has led to an increase in the number of people who are seeking treatment for this condition, thereby driving the growth of the oral hypoglycemic agents and insulin analogue market.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Hypoglycemic Agents and Insulin Analogues Market Research Report
By Type
Insulin Secretagogues, Alpha-glucosidase Inhibitors, Insulin Sensitizers
By Application
Hospitals, Drug Store, Others
By Companies
Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk, Eli Lilly, Tonghua Dongbao, United Laboratory, Jiangsu Wanbang, Sanofi-Aventis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Oral Hypoglycemic Agents and Insulin Analogues Market Report Segments:
The global Oral Hypoglycemic Agents and Insulin Analogues market is segmented on the basis of:
Types
Insulin Secretagogues, Alpha-glucosidase Inhibitors, Insulin Sensitizers
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Drug Store, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi-Aventis
- Ganlee
- Biocon
- Novo Nordisk
- Eli Lilly
- Tonghua Dongbao
- United Laboratory
- Jiangsu Wanbang
- Sanofi-Aventis
Highlights of The Oral Hypoglycemic Agents and Insulin Analogues Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Insulin Secretagogues
- Alpha-glucosidase Inhibitors
- Insulin Sensitizers
- By Application:
- Hospitals
- Drug Store
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Hypoglycemic Agents and Insulin Analogues Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral hypoglycemic agents and insulin analogues are medications that help to lower blood sugar levels. These medications work by reducing the amount of glucose in the blood.
Some of the major players in the oral hypoglycemic agents and insulin analogues market are Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk, Eli Lilly, Tonghua Dongbao, United Laboratory, Jiangsu Wanbang, Sanofi-Aventis.
The oral hypoglycemic agents and insulin analogues market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Hypoglycemic Agents and Insulin Analogues Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Hypoglycemic Agents and Insulin Analogues Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Hypoglycemic Agents and Insulin Analogues Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Hypoglycemic Agents and Insulin Analogues Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size & Forecast, 2020-2028
4.5.1 Oral Hypoglycemic Agents and Insulin Analogues Market Size and Y-o-Y Growth
4.5.2 Oral Hypoglycemic Agents and Insulin Analogues Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Insulin Secretagogues
5.2.2 Alpha-glucosidase Inhibitors
5.2.3 Insulin Sensitizers
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Drug Store
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Hypoglycemic Agents and Insulin Analogues Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Hypoglycemic Agents and Insulin Analogues Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Insulin Secretagogues
9.6.2 Alpha-glucosidase Inhibitors
9.6.3 Insulin Sensitizers
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Drug Store
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Insulin Secretagogues
10.6.2 Alpha-glucosidase Inhibitors
10.6.3 Insulin Sensitizers
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Drug Store
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Insulin Secretagogues
11.6.2 Alpha-glucosidase Inhibitors
11.6.3 Insulin Sensitizers
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Drug Store
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Insulin Secretagogues
12.6.2 Alpha-glucosidase Inhibitors
12.6.3 Insulin Sensitizers
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Drug Store
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Insulin Secretagogues
13.6.2 Alpha-glucosidase Inhibitors
13.6.3 Insulin Sensitizers
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Drug Store
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Hypoglycemic Agents and Insulin Analogues Market: Competitive Dashboard
14.2 Global Oral Hypoglycemic Agents and Insulin Analogues Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi-Aventis
14.3.2 Ganlee
14.3.3 Biocon
14.3.4 Novo Nordisk
14.3.5 Eli Lilly
14.3.6 Tonghua Dongbao
14.3.7 United Laboratory
14.3.8 Jiangsu Wanbang
14.3.9 Sanofi-Aventis
